Discounted Cash Flow (DCF) Analysis Unlevered

Diffusion Pharmaceuticals Inc. (DFFN)

$ 0.3904
+0.01 (+2.17%)
Stock DCF: - | 0.3904 | undervalue

Operating Data

Year
A/P
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.3,904
Beta 1.374
Diluted Shares Outstanding 53.83
Cost of Debt
Tax Rate 10.56
After-tax Cost of Debt 4.47%
Risk-Free Rate
Market Risk Premium
Cost of Equity 7.965
Total Debt 0.15
Total Equity 21.02
Total Capital 21.17
Debt Weighting 0.70
Equity Weighting 99.30
Wacc

Build Up Free Cash

Year
A/P
2016
Projected
2017
Projected
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 1.98%43.62%2.33%-2.90%10.56%11.12%11.12%11.12%11.12%11.12%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -0-0.45--------
UFCF ----------
WACC
PV UFCF ----------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 7.94
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -18.37
Equity Value -
Shares Outstanding 53.83
Equity Value Per Share -